OLMA OLEMA PHARMACEUTICALS INC Investments/Divestments 8-K Filing 2023 - Clinical Study Results Olema Pharmaceuticals announced interim results from clinical studies of palazestrant in combination with CDK4/6 inhibitors and a Phase 3 trial poster presentation.Get access to all SEC 8-K filings of the OLEMA PHARMACEUTICALS INC